Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for MS-related fatigue
NCT06064162Phase 1Completed
- Sponsor
- Alta Bates Summit Medical Center
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ketamine in multiple sclerosis (MS) (2 arms), sponsored by Alta Bates Summit Medical Center. Primary endpoint: Improve Fatigue Scores at 28 days. Started Dec 2023; status: completed.
02
Drugs
ketamine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06064162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06064162.